Dose clip assembly for syringe
By designing subretinal delivery devices for the superchoroidal cavity pathway, the non-invasive insertion technology of flexible cannula and needles solves the problem of inaccessibility of macular degeneration areas, and achieves effective delivery of therapeutic agents and localized treatment.
Patent Information
- Application Number
- CN202411283901.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-10-11
- Filing Date
- 2020-10-08
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively deliver therapeutic agents to the macular degeneration area of the eye, especially since the macula is located at the back of the eye and under the fragile retinal layer, and it is difficult to approach and treat in a practical way.
Designed an instrument for subretinal administration from the supramolecular pathway, including a flexible cannula and a propellable needle, ensuring the cannula and needle in the eye through sclerotomy and the use of suture ring assembly. Non-traumatic insertion and positioning, thereby delivering therapeutic agents to the subretinal space.
Delivering therapeutic agents to the subretinal space, especially the macular degeneration area, is achieved without trauma, improving the localization and effectiveness of the treatment and reducing damage to the eyes.
Smart Images

Figure CN118948524A_ABST
Abstract
Description
[0001] This application is a divisional application of an international application entering the Chinese national phase with an application date of October 8, 2020, international application number PCT / IB2020 / 000836, national application number 202080070985.9, and name “Dose clamp assembly for a syringe”. Technical Field
[0002] The present application relates to the field of syringes. Background Art
[0003] The human eye consists of multiple layers. The white outer layer is the sclera, which surrounds the choroid layer. The retina is inside the choroid layer. The sclera contains collagen and elastic fibers that provide protection for the choroid and retina. The choroid layer includes a vasculature that supplies oxygen and nutrients to the retina. The retina includes light-sensitive tissue, including rods and cones. The macula is located in the center of the retina at the back of the eye, usually centered on the axis that passes through the center of the eye's lens and cornea (i.e., the optical axis). The macula provides central vision, particularly through the cones.
[0004] Macular degeneration is a medical disease that affects the macula, so people with macular degeneration may lose or degenerate their central vision while retaining a certain degree of peripheral vision. Macular degeneration can be caused by a variety of factors, including age (also known as "AMD") and genetics. Macular degeneration may occur in a "dry" (non-exudative) form, in which cellular debris called drusen accumulate between the retina and the choroid, resulting in areas of geographic atrophy. Macular degeneration may also occur in a "wet" (exudative) form, in which blood vessels grow upward from the choroid behind the retina. Although people with macular degeneration may retain a certain degree of peripheral vision, the loss of central vision may have a significant negative impact on quality of life. In addition, the quality of the peripheral vision that is retained may decrease, and in some cases, it may also be lost. Therefore, it may be necessary to provide treatment for macular degeneration to prevent or reverse the vision loss caused by macular degeneration. In some cases, it may be desirable to provide such treatment in a highly localized manner, such as by delivering a therapeutic substance to the subretinal layers (below the neurosensory layers of the retina and above the retinal pigment epithelium) directly adjacent to an area of geographic atrophy near the macula. However, because the macula is located at the back of the eye and beneath delicate retinal layers, it can be difficult to access the macula in a practical manner.
[0005] While a variety of surgical methods and instruments have been made and used to treat the eye, it is believed that no one prior to the inventors has made or used the invention described in the appended claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0006] Although this specification concludes with claims that particularly point out and distinctly claim the technology, it is believed that the technology will be better understood through the following description of certain examples taken in conjunction with the accompanying drawings, in which like reference numerals represent like elements, and in which:
[0007] Figure 1 A perspective view showing an example of a device for subretinal administration of a therapeutic agent from a suprachoroidal approach;
[0008] Figure 2A Shows Figure 1 a perspective view of the distal end of the cannula of the illustrated instrument with the needle retracted within the cannula;
[0009] Figure 2B Shows Figure 2A a perspective view of the distal end of the cannula shown with the needle extending from the cannula;
[0010] Figure 3 Shows Figure 1 A perspective view of the device shown, mounted near a patient and in combination with other equipment;
[0011] Figure 4A A cross-sectional side view of a patient's eye is shown;
[0012] Figure 4B Shows Figure 4A Cross-sectional lateral view of the mid-eye with suture loops attached to the eye and a sclerotomy being performed;
[0013] Figure 4C Shows Figure 4A Cross-sectional side view of the eye, where Figure 2A The cannula in is inserted through the sclerotomy opening between the sclera and choroid of the eye;
[0014] Figure 4D Shows Figure 4A a cross-sectional side view of the mid-eye with the distal end of the cannula positioned near the target site;
[0015] Figure 4E Shows Figure 4A Cross-sectional side view of the eye, where Figure 2B The needle shown is advanced through the choroid to enter the subretinal space at the target location;
[0016] Figure 4F Shows Figure 4A Cross-sectional side view of the eye, where Figure 2B The needle shown dispenses a first volume of a leading bubble fluid to separate the retinal region from the choroidal region at a target location;
[0017] Figure 4G Shows Figure 4A Cross-sectional side view of the eye, where Figure 2B The needle is shown dispensing the therapeutic agent between the retinal and choroidal regions at the target location;
[0018] Figure 5 A perspective view showing an example of a dose clip assembly for use with a syringe;
[0019] Figure 6 Shows Figure 5 Another perspective view of the dose clip assembly is shown;
[0020] Figure 7 Shows Figure 5 An exploded perspective view of the dose clip assembly is shown;
[0021] Figure 8 Shows Figure 5 A perspective view of a lower member of the dose clamp assembly is shown;
[0022] Fig. 9 Shows Figure 8 Another perspective view of the lower member shown;
[0023] Fig.10 Shows Figure 5 a perspective view of an upper member of the dose clip assembly shown;
[0024] Fig.11 Shows Fig.10 another perspective view of the upper member shown;
[0025] Fig. 12A Shows Figure 5 a top view of the dose clip assembly shown with the upper member in a first pivoted position relative to the lower member;
[0026] Fig. 12B Shows Figure 5 a top view of the dose clip assembly shown with the upper member in a second pivoted position relative to the lower member;
[0027] Fig.13 Shown along Figure 5 The line 13-13 in Figure 5 a cross-sectional view of the dose clip assembly shown;
[0028] Fig.14A shows a syringe and Figure 5 a perspective view of the dose clamp assembly shown with the syringe separated from the dose clamp assembly and the syringe coupled to a fluid source;
[0029] Fig. 14B Shows Figure 5The dose clip assembly shown and Fig.14A a perspective view of the syringe shown with the syringe separated from the dose clamp assembly and the syringe having drawn fluid from a fluid source;
[0030] Fig. 14C Shows Figure 5 The dose clip assembly shown and Fig.14A A perspective view of the syringe shown, wherein the syringe is coupled to the dose clamp assembly and the syringe contains Fig. 14B wherein the upper member of the dose clamp assembly is in a second pivotal position relative to the lower member of the dose clamp assembly;
[0031] Fig.14D Shows Figure 5 The dose clip assembly shown and Fig.14A A perspective view of the syringe shown, wherein the syringe is coupled to the dose clamp assembly and the syringe contains Fig. 14B The syringe is provided with a first pivoted position of the upper member of the dose clamp assembly relative to the lower member of the dose clamp assembly. Figure 1 The device connections shown;
[0032] Fig.14E Shows Figure 5 The dose clip assembly shown and Fig.14A A perspective view of a syringe shown in FIG. 1 wherein the syringe is coupled to a dose clamp assembly, wherein an upper member of the dose clamp assembly is in a first pivoted position relative to a lower member of the dose clamp assembly, and wherein the syringe is coupled to a dose clamp assembly. Figure 1 The device is coupled as shown, and the plunger of the syringe is advanced to a first longitudinal position relative to the syringe barrel;
[0033] Fig.14F Shows Figure 5 The dose clip assembly shown and Fig.14A A perspective view of a syringe shown in FIG. 1 wherein the syringe is coupled to a dose clamp assembly and an upper member of the dose clamp assembly is in a second pivoted position relative to a lower member of the dose clamp assembly, the syringe and Figure 1 The device is coupled as shown, and the plunger of the syringe is maintained in a first longitudinal position relative to the syringe barrel;
[0034] Figure 14G Shows Figure 5 The dose clip assembly shown and Fig.14A A perspective view of a syringe shown in FIG. 1 wherein the syringe is coupled to a dose clamp assembly, an upper member of the dose clamp assembly being in a second pivoted position relative to a lower member of the dose clamp assembly, and the syringe is coupled to the dose clamp assembly. Figure 1 The device is coupled as shown, and the plunger of the syringe is maintained in a second longitudinal position relative to the syringe barrel;
[0035] Fig.15AShows that Fig.14E The operating status shown Figure 5 The dose clip assembly shown and Fig.14A an enlarged perspective view of the syringe shown; and
[0036] Fig. 15B Shows that Figure 14G The operating status shown Figure 5 The dose clip assembly shown and Fig.14A An enlarged perspective view of the syringe is shown.
[0037] The drawings are not intended to be limiting in any way, and it is contemplated that various embodiments of the present technology may be implemented in various other ways, including those not necessarily depicted in the drawings. The accompanying drawings, which are incorporated in and form a part of the specification, illustrate several aspects of the present technology and, together with the description, serve to explain the principles of the technology; however, it should be understood that the technology is not limited to the precise arrangements shown. DETAILED DESCRIPTION
[0038] The following description of certain examples of the present technology should not be used to limit the scope of the present technology. Other examples, features, aspects, embodiments and advantages of the present technology will become apparent to those skilled in the art through the following description, which is one of the best modes for implementing the present technology contemplated for illustrative purposes. As will be appreciated, the technology described herein can have other different and obvious aspects, all of which do not depart from the present technology. Therefore, the drawings and descriptions should be considered illustrative, not restrictive.
[0039] It should also be understood that any one or more of the teachings, representations, embodiments, examples, etc. described herein may be combined with any one or more other teachings, representations, embodiments, examples, etc. described herein. Therefore, the teachings, expressions, embodiments, examples, etc. described below should not be viewed in isolation from each other. Various suitable ways of combining the teachings herein will be apparent to those skilled in the art in light of the teachings herein. Such modifications and variations are intended to be included within the scope of the claims.
[0040] For clarity, the terms "proximal" and "distal" are defined herein relative to a surgeon or other operator holding a surgical instrument having a distal surgical end effector. The term "proximal" refers to a position of an element closer to the surgeon or other operator, and the term "distal" refers to a position of an element closer to the surgical end effector of the surgical instrument and further away from the surgeon or other operator.
[0041] I. Devices for subretinal delivery of therapeutic agents
[0042] Figure 1An example of an apparatus 100 is shown, which is configured for use in a procedure for subretinal administration of a therapeutic agent to a patient's eye from a suprachoroidal approach. The apparatus 100 includes a body 110 and a flexible cannula 130 extending distally from the body 110. The cannula 130 of this example has a generally rectangular cross-section, although any other suitable cross-sectional profile (e.g., elliptical, etc.) may also be used. The cross-sectional profile of the cannula 130 is configured to enable the cannula 130 to be passed atraumatically along the suprachoroidal space, which will be described in more detail below. The cannula 130 is generally configured to support a needle 150 that can slide within the cannula 130, which will be described in more detail below.
[0043] In the present example, the cannula 130 comprises a flexible material, such as polyether block amide (PEBA). Of course, any other suitable material or combination of materials may be used. In the present example, the cannula 130 has a cross-sectional profile dimension of approximately 1.6 mm (width) x approximately 0.6 mm (height), and the length of the cannula 130 is approximately 80 mm. Alternatively, any other suitable dimensions may be used. The cannula 130 of the present example is flexible enough to conform to the specific structure and contours of the patient's eye, yet the cannula 130 has sufficient column strength to allow the cannula 130 to be advanced between the sclera and choroid of the patient's eye without buckling. Figure 2A-2B As shown, the cannula 130 includes a laterally oriented opening 134 at a distal end 132 of the cannula 130. As will be described in more detail below, the distal end 132 is atraumatic and is configured to provide separation between the scleral layer and the choroidal layer, thereby enabling the cannula 130 to be advanced between these layers without causing trauma to the scleral layer or the choroidal layer.
[0044] By way of example only, cannula 130 may be configured and operated in accordance with at least some of the teachings of: U.S. Publication No. 2015 / 0223977, entitled “Method and Apparatus for Subretinal Administration of Therapeutic Agent,” published on August 13, 2015 (the disclosure of which is incorporated herein by reference); U.S. Publication No. 2017 / 0360607, entitled “Apparatus and Method to From Entry Bleb for Subretinal Delivery of Therapeutic Agent,” published on December 21, 2017 (the disclosure of which is incorporated herein by reference); and / or U.S. Publication No. 2017 / 0360606, entitled “Injection Device for Subretinal Delivery of Therapeutic Agent,” published on December 21, 2017 (the disclosure of which is incorporated herein by reference).
[0045] like Figure 2B As shown, needle 150 can be advanced distally and extend from opening 134. The needle 150 of this example has a sharp distal tip 152 and is defined with an inner cavity (not shown). The distal tip 152 of this example has a lancet-shaped configuration. In some other forms, the distal tip 152 has a three-bevel configuration or any other configuration, as described in U.S. Publication No. 2015 / 0223977 (the disclosure of which is incorporated herein by reference) entitled "Method and Apparatus for Subretinal Administration of Therapeutic Agent" published on August 13, 2015. In view of the teachings herein, other suitable forms that the distal tip 152 can take will be apparent to those skilled in the art.
[0046] The needle 150 of this example comprises a stainless steel hypodermic needle, which is sized to deliver and aspirate fluids while being small enough to minimize accidental trauma when the needle 150 penetrates the tissue structure of the patient's eye, as will be described in more detail below. Although stainless steel is used in this example, any other suitable material may be used, including but not limited to nitinol, etc.
[0047] By way of example only, needle 150 may be 35 gauge with an inner diameter of 100 μm, although other suitable sizes may be used. For example, the outer diameter of needle 150 may be in the range of 27 to 45 gauge; or more specifically in the range of 30 to 42 gauge; or more specifically in the range of 32 to 39 gauge. As another merely illustrative example, the inner diameter of needle 150 may be in the range of about 50 μm to about 200 μm; or more specifically in the range of about 50 μm to about 150 μm; or more specifically in the range of about 75 μm to about 125 μm.
[0048] In some aspects, a needle guide (not shown) is disposed within the cannula 130 to guide the needle 150 along a predetermined angle as the needle 150 exits through the opening 134. By way of example only, the exit angle of the needle 150 may be in a range of about 5° to about 30° relative to the longitudinal axis of the cannula 130; or more specifically, in a range of about 5° to about 20° relative to the longitudinal axis of the cannula 130; or more specifically, in a range of about 5° to about 10° relative to the longitudinal axis of the cannula 130; or more specifically, in a range of about 7° and about 9° relative to the longitudinal axis of the cannula 130. In addition to or in lieu of disposing a needle guide within the cannula 130, the needle 150 may be resiliently biased to assume a curved configuration, thereby providing an exit angle that varies depending on the extent to which the needle 150 is advanced distally relative to the cannula 130. By way of example only, needle 150 can have a preformed curve in accordance with at least some of the teachings of U.S. Publication No. 2017 / 0258988, published on September 14, 2017, entitled “Apparatus for Subretinal Administration of Therapeutic Agent via a Curved Needle,” the disclosure of which is incorporated herein by reference.
[0049] In the present example, the generally rectangular, generally oval, or other generally flat cross-sectional profile of the cannula 130 prevents the cannula 130 from rotating about the longitudinal axis of the cannula 130 when the cannula 130 is disposed in the suprachoroidal space, as will be described in more detail below. This allows the opening 134 to have a consistent and predictable orientation, thereby providing a consistent and predictable exit path for the needle 150 as the needle 150 is advanced distally relative to the cannula 130, as will be described in more detail below.
[0050] like Figure 1As shown, the instrument 100 of this example also includes an actuation knob 120 located at the top 114 of the body 110. The actuation knob 120 can be rotated relative to the body 110 so that the needle 150 can be selectively translated in the longitudinal direction relative to the sleeve 130. Specifically, the actuation knob 120 can be rotated in a first angular direction to drive the needle 150 distally relative to the sleeve 130; and can be rotated in a second angular direction to drive the needle 150 proximally relative to the sleeve 130. By way of example only, the instrument 100 can provide such functionality in accordance with at least some of the teachings in U.S. Publication No. 2017 / 0360606 (the disclosure of which is incorporated herein by reference) and / or U.S. Publication No. 2017 / 0360607 (the disclosure of which is incorporated herein by reference). In view of the teachings herein, other suitable ways in which the rotational motion of the knob 120 can be converted into a linear translation of the needle 150 will be apparent to those skilled in the art. Similarly, other suitable ways in which needle (150) may be actuated in a longitudinal direction relative to cannula (130) will be apparent to those of ordinary skill in the art in view of the teachings herein.
[0051] like Figure 1 As shown, the catheter assembly 140 extends proximally from the body 110. The catheter assembly 140 is configured to include one or more fluid conduits (not shown) in fluid communication with the needle 150. Such fluid conduits may include one or more hoses, etc. In some embodiments, the catheter assembly 140 also includes one or more cables. By way of example only, such cables may provide data signal communication from one or more sensors in the body 110 to a processor away from the device 100. Such configurations and operability may be implemented according to at least some of the teachings in U.S. Publication No. 2017 / 0360606 (the disclosure of which is incorporated herein by reference) and / or U.S. Publication No. 2017 / 0360607 (the disclosure of which is incorporated herein by reference). By way of further example only, such cables may provide power communication to one or more electric components in the body 110. In view of the teachings herein, various suitable ways of implementing power and / or signals by one or more cables in the catheter assembly 140 and one or more electric related components in the body 110 are apparent to those skilled in the art. Alternatively, some types of catheter assemblies 140 may have no cables at all; and the body 110 may have no sensors, electrical components, etc.
[0052] The features and operability of the device 100 may be varied in a variety of ways. Among other things, the device 100 may be based on U.S. Publication No. 2015 / 0223977, published on August 13, 2015, entitled “Method and Apparatus for Subretinal Administration of Therapeutic Agents” (the disclosure of which is incorporated herein by reference), U.S. Publication No. 2015 / 0351958, published on December 10, 2015, entitled “Therapeutic Agent Delivery Device with Convergent Lumen” (the disclosure of which is incorporated herein by reference), U.S. Publication No. 2015 / 0351959, published on December 10, 2015, entitled “Sub-Retinal Tangential Needle Catheter Guide and Introducer” (the disclosure of which is incorporated herein by reference), U.S. Publication No. 2015 / 0351959, published on December 10, 2015, entitled “Sub-Retinal Tangential Needle Catheter Guide and Introducer” (the disclosure of which is incorporated herein by reference), U.S. Publication No. 2015 / 0351959, published on March 17, 2016, entitled “Method and Apparatus for Sensing Position Between Layers of an The invention relates to a method for modifying a therapeutic agent according to the present invention, and the ...
[0053] II. Procedures for delivering therapeutic agents from the suprachoroidal space to the subretinal space
[0054] Figure 3The apparatus 100 is shown as being placed relative to a patient. In this example, a drape 12 is placed on the patient, and an opening 18 is formed in the drape 12 near the patient's eye 301. An opener 16 is used to keep the eye 301 open. A fixture 14 is positioned adjacent to the eye 301. The fixture 14 can be used to fix an apparatus, such as a viewing mirror, relative to the patient. A magnetic pad 30 is attached to the drape 12 near the opening 18 near the eye 301. The apparatus 100 is placed on the magnetic pad 30 and is removably fixed thereto by magnetic attraction. In this example, one or more permanent magnets (not shown) are located near the bottom 112 within the body 110; and these magnets are magnetically attracted to one or more ferrous elements (not shown) contained within the magnetic pad 30. By way of example only, these magnets and the magnetic pad 30 can be configured according to at least some of the teachings of U.S. Publication No. 2017 / 0360606 (the disclosure of which is incorporated herein by reference). The instrument 100 is oriented so that the flexible sleeve 130 of the instrument 100 can be inserted into the eye 301. Figures 4A-4F An example of a procedure for inserting and positioning cannula 130 in eye 301 is described in more detail.
[0055] Continue to refer Figure 3 , the catheter assembly 140 can be coupled to a fluid source such as a conventional syringe 50. The syringe 50 in this example includes a barrel 52 and a plunger 54. The barrel 52 is in fluid communication with the needle 150 via the catheter assembly 140. Although only one syringe 50 is coupled to the catheter assembly 140 in this example, in other cases, two or more syringes 50 can be coupled to the catheter assembly 140. The two or more syringes 50 can be connected to the catheter assembly 140 via one or more "Y" fittings, manifolds, or any other structure, which will be apparent to those skilled in the art in view of the teachings herein.
[0056] Figures 4A-4G An example of a procedure that can be performed using the above-described apparatus is shown, which uses a suprachoroidal approach to deliver a therapeutic agent to the subretinal space of the eye 301. By way of example only, the methods described herein can be used to treat macular degeneration and / or other eye diseases. Although the procedures described herein are discussed in the context of treating age-related macular degeneration, such limitation is not intended or implied. For example, in some alternative procedures, the same techniques described herein can be used to treat retinitis pigmentosa, diabetic retinopathy, and / or other eye diseases. In addition, the procedures described herein can be used to treat dry or wet age-related macular degeneration, as well as other conditions.
[0057] In this example, the operator begins the procedure by immobilizing tissue surrounding the patient's eye 301 (e.g., eyelid) using an instrument such as a retractor 16 and / or any other suitable instrument for immobilization. The immobilization described herein refers to the tissue surrounding the eye 301, while the eye 301 itself may remain free to move. Figure 4A As shown, once the tissue surrounding the eye 301 is fixed, an eye chandelier port 314 is inserted into the eye 301 to provide intraocular illumination while viewing the interior of the eye 301 through the pupil. In this example, the eye chandelier port 314 is positioned in the lower medial quadrant so that a superior temporal quadrant sclerotomy can be performed. The eye chandelier port 314 is positioned to direct light to the interior of the eye 301 to illuminate at least a portion of the retina 308 (e.g., including at least a portion of the macula). It will be appreciated that such illumination corresponds to an area of the eye 301 that is targeted for delivery of a therapeutic agent.
[0058] In this example, Figure 4A At the stage shown, only the chandelier port 314 is inserted, and the optical fiber 315 has not yet been inserted into the port 314. In some other embodiments, the optical fiber 315 can be inserted into the chandelier port 314 at this stage. In either case, a microscope can optionally be used to visually inspect the eye to confirm the correct positioning of the eye chandelier port 314 relative to the target site. Although Figure 4A A certain positioning of eye chandelier port (314) is shown, but it will be apparent to one of ordinary skill in the art in view of the teachings herein that eye chandelier port (314) may have any other suitable positioning.
[0059] Once the eye chandelier port 314 has been positioned, the conjunctiva may be dissected by cutting a flap in the conjunctiva and pulling the flap backwards to access the sclera 304. After such dissection is complete, the exposed surface 305 of the sclera 304 may optionally be blanched using a cautery tool to minimize bleeding. Once the conjunctival dissection is complete, the exposed surface 305 of the sclera 304 may optionally be dried using a WECK-CEL or other suitable absorbent device.
[0060] The template may then be used to mark the eye 20, as described in U.S. Publication No. 2015 / 0223977, the disclosure of which is incorporated herein by reference, and / or U.S. Publication No. 2017 / 0360605, entitled “Guide Apparatus for Tangential Entry into Suprachoroidal Space,” published on December 21, 2017, the disclosure of which is incorporated herein by reference. The operator may then use the visual guide created by the template to attach the suture ring assembly 332 and perform a sclerotomy using a conventional scalpel 313 or other suitable cutting instrument, such as Figure 4B As shown. By way of example only, the sewing ring assembly 70 can be formed according to at least some of the teachings in U.S. Publication No. 2015 / 0223977 (the disclosure of which is incorporated herein by reference). Alternatively, instead of the sewing ring assembly 70, the operator can install the guide pin according to at least some of the teachings in U.S. Publication No. 2017 / 0360605 (the disclosure of which is incorporated herein by reference).
[0061] The sclerotomy procedure forms a small incision through the sclera 304 of the eye 301. The sclerotomy is performed with particular care to avoid penetrating the choroid 306. Thus, the sclerotomy procedure provides access to the space between the sclera 304 and the choroid 306. Once the incision is made in the eye 301, a blunt dissection may optionally be performed to partially separate the sclera 304 from the choroid 306. Such a dissection may be performed using a small, blunt, elongated instrument, as will be apparent to one of skill in the art in light of the teachings herein.
[0062] As the sclerotomy procedure progresses, the operator may insert the cannula 130 of the instrument 100 through the incision 316 into the space between the sclera 304 and the choroid 306. Figure 4CAs shown, the cannula 130 is guided through the sewing ring assembly 332 and enters the incision. The sewing ring assembly 332 can stabilize the cannula 130 during the insertion process. In addition, the sewing ring assembly 332 keeps the cannula 130 in an orientation that is generally tangential to the incision. When the cannula 130 is guided through the incision, this tangential orientation can reduce trauma. When the cannula 130 is inserted into the incision through the sewing ring assembly 332, the operator can use forceps or other instruments to further guide the cannula 130 along an atraumatic path. Of course, the use of forceps or other instruments is only optional and can be omitted in some examples. As described above, a guide pin (or other device) can be used instead of the sewing ring assembly 332. The cannula 130 is advanced until the distal end 132 is positioned near the target area of the subretinal space, located on the opposite side of the choroid 306. In view of the teachings herein, various suitable ways of visualizing the distal end 132 so as to observe the correct positioning of the distal end 132 will be obvious to those skilled in the art.
[0063] Although not shown, in some examples, the cannula 130 can include one or more markings on the surface of the cannula 130 to indicate various insertion depths. Although merely optional, such markings may help an operator identify the correct insertion depth when guiding the cannula 130 along an atraumatic path. For example, an operator can visually observe the position of these markings relative to the suture ring assembly 332 and / or relative to the incision in the sclera 304 as an indication of the depth of insertion of the cannula 130 into the eye 301. By way of example only, one such marking may correspond to an insertion depth of approximately 6 mm for the cannula 130.
[0064] like Figure 4D As shown, once the cannula 130 is at least partially inserted into the eye 301, the operator can insert the optical fiber 315 into the eye chandelier port 314 if the optical fiber 315 has not been inserted at this stage. With the eye chandelier port 314 in place and assembled with the optical fiber 315, the operator can activate the eye chandelier port 314 by directing light through the optical fiber 315 to provide illumination to the eye 301, thereby visualizing the interior of the eye 301. At this point, the positioning of the cannula 130 can optionally be further adjusted to ensure its correct positioning relative to the retinal geographic atrophy area 308. In some cases, the operator may wish to rotate the eye 301, such as by pulling on the sewing ring assembly 332, so that the pupil of the eye 301 is facing the operator, thereby optimizing the visualization of the interior of the eye 301 through the pupil.
[0065] Figure 4C-4DThe cannula 130 is shown being guided between the sclera 304 and the choroid 306 to position the distal end 132 of the cannula 130 at a delivery site of the therapeutic agent. In this example, the delivery site corresponds to a generally posterior region of the eye 301 adjacent to an area of geographic atrophy of the retina 308. In particular, the delivery site of this example is above the macula, in the potential space between the neurosensory retina and the retinal pigment epithelium. By way of example only, when the cannula 130 is in Figure 4C-4D While advancing within the range of motion shown, the operator can rely on direct visualization of a microscope directed through the pupil of eye 301, with illumination provided by optical fiber 315 and port 314. Cannula 130 can be at least partially visualized through the retina 308 and choroid 306 of eye 301. In approaches that use optical fibers to emit visible light via the distal end of cannula 130, visual tracking can be enhanced.
[0066] Once the cannula 130 is advanced to Figure 4D At the delivery site shown, the operator may advance the needle 150 of the device 100 by actuating the knob 120 as described above. Figure 4E 308, the needle 150 is advanced relative to the cannula 130 such that the needle 150 pierces the choroid 306 without penetrating the retina 308. Just prior to penetrating the choroid 306, the needle 150 may appear under direct visualization to "push" the surface of the choroid 306. In other words, the needle 150 may deform the choroid 306 by pushing the choroid 306 upward, thereby providing a tent pole-like configuration (deforming the top of a tent). The operator may use this visual phenomenon to identify whether the choroid 306 is about to be pierced and where the puncture will ultimately occur. The specific amount of advancement of the needle 150 sufficient to begin to "push" the choroid 306 and subsequently pierce the choroid 306 may be any suitable amount, which may be determined by a variety of factors, such as, but not limited to, general patient anatomy, local patient anatomy, operator preference, and / or other factors. As described above, an example of a range of advancement of the needle 150 may be between approximately 0.25 mm and approximately 10 mm; or more specifically, between approximately 2 mm and approximately 6 mm.
[0067] In this example, after the operator confirms that the needle 150 has been properly advanced by observing the above-mentioned propping effect, the operator injects a balanced salt solution (BSS) or other similar solution as the needle 150 is advanced relative to the cannula 130. Such BSS can form a leading bubble 340 in front of the needle 150 as the needle 150 is advanced through the choroid 306. The leading bubble 340 may be desired for two reasons. First, if the needle 150 is advanced through the choroid 306, the leading bubble 340 may be needed. Figure 4FAs shown, the leading bubble 340 can provide a further visual indication to the operator to indicate when the needle 150 is correctly positioned at the delivery site. Secondly, once the needle 150 has penetrated the choroid 306, the leading bubble 340 can provide a barrier between the needle 150 and the retina 308. This barrier can push the retinal wall outward, thereby minimizing the risk of retinal perforation when the needle 150 is advanced to the delivery site. In some forms, the foot pedal is actuated to drive the leading bubble 340 out of the needle 150. Alternatively, in view of the teachings herein, other suitable features that can be used to drive the leading bubble 340 out of the needle 150 will be apparent to those skilled in the art.
[0068] Once the operator observes the leading bubble 340, the operator can stop infusing the BSS, leaving the Figure 4F A pocket of fluid is shown. Next, the therapeutic agent 342 can be infused by actuating the syringe 50 or some other fluid delivery device as described in various references cited herein. The delivered therapeutic agent 342 can be any suitable therapeutic agent for treating eye diseases. Some merely illustrative examples of suitable therapeutic agents can include, but are not necessarily limited to, drugs with smaller or larger molecules, therapeutic cell solutions, certain gene therapy solutions, tissue plasminogen activators, and / or any other suitable therapeutic agent that is obvious to those skilled in the art based on the teachings herein. By way of example only, the therapeutic agent 342 can be provided based on at least some of the teachings in U.S. Patent No. 7,413,734, entitled "Treatment of Retinitis Pigmentosa with Human Umbilical Cord Cells" issued on August 19, 2008 (the disclosure of which is incorporated herein by reference). In addition to being used to deliver the therapeutic agent 342, or as an alternative, the device 100 and its variations can be used to provide drainage and / or perform other operations.
[0069] In this example, the amount of therapeutic agent 342 ultimately delivered to the delivery site is approximately 50 μL, but any other suitable amount may be delivered. In some embodiments, a foot pedal is actuated to push therapeutic agent 342 out of needle 150. Alternatively, other suitable features for driving therapeutic agent 342 out of needle 150 will be apparent to those of skill in the art in view of the teachings herein. Figure 4G As shown, the delivery of therapeutic agent 342 can be visualized by the expansion of a fluid pocket. As shown, when therapeutic agent 342 is injected into the subretinal space, therapeutic agent 342 is substantially mixed with the fluid of leading bubble 340.
[0070] Once delivery is complete, the needle 150 can be retracted by rotating the knob 120 in a direction opposite to the direction in which the needle 150 was advanced; the cannula 130 can then be withdrawn from the eye 301. Due to the size of the needle 150, the site where the needle 150 penetrates the choroid 306 is self-sealing, so no further steps need to be taken to seal the delivery site through the choroid 306. The suture ring assembly 332 and chandelier 314 can be removed, and the incision in the sclera 304 can be closed using any suitable conventional technique.
[0071] As described above, the aforementioned procedures may be implemented to treat patients with macular degeneration. In some such cases, the therapeutic agent 342 delivered by the needle 150 may include cells derived from the postpartum umbilical cord and placenta. As described above, by way of example only, the therapeutic agent 342 may be provided according to at least some of the teachings in U.S. Pat. No. 7,413,734, entitled "Treatment of Retinitis Pigmentosa with Human Umbilical Cord Cells," issued on August 19, 2008, the disclosure of which is incorporated herein by reference. Alternatively, in addition to or in lieu of those described in U.S. Pat. No. 7,413,734 and / or elsewhere herein, the needle 150 may be used to deliver any other suitable substance. By way of example only, the therapeutic agent 342 may include various drugs, including but not limited to small molecules, macromolecules, cells and / or gene therapy agents. It should also be understood that macular degeneration is merely an illustrative example of a condition that may be treated by the procedures described herein. It is obvious to one of ordinary skill in the art that other biological diseases that may be addressed using the apparatus and procedures described herein are apparent.
[0072] The procedures described above may be implemented according to any of the teachings of the following documents: U.S. Publication No. 2015 / 0223977, entitled “Method and Apparatus for Subretinal Administration of Therapeutic Agent,” published on August 13, 2015 (the contents of which are incorporated herein by reference); U.S. Publication No. 2015 / 0351958, entitled “Therapeutic Agent Delivery Device with Convergent Lumen,” published on December 10, 2015 (the contents of which are incorporated herein by reference); U.S. Publication No. 2015 / 0351959, entitled “Sub-Retinal Tangential Needle Catheter Guide and Introducer,” published on December 10, 2015 (the contents of which are incorporated herein by reference); U.S. Publication No. 2015 / 0351959, entitled “Sub-Retinal Tangential Needle Catheter Guide and Introducer,” published on March 17, 2016 (the contents of which are incorporated herein by reference); and / or U.S. Publication No. 2016 / 0081849, entitled “Therapeutic Agent Delivery Device,” published March 24, 2016, which is incorporated herein by reference.
[0073] III. Example of a Dosing Clip for a Syringe for Delivering Fluid to the Subretinal Space
[0074] Those skilled in the art will recognize that ensuring that the appropriate amount of fluid is delivered to the subretinal space of the eye 301 may be critical, particularly given the anatomical limitations of the subretinal space. In the case of delivering the leading bubble 340 and therapeutic agent 342, delivering too much fluid may result in an undesirable degree of detachment of the retina 308 from the choroid 306; perhaps even to the extent of causing rupture of the retina 308. In the case of delivering the leading bubble 340, delivering too little fluid may result in insufficient separation between the retina 308 and the choroid 306, which may result in insufficient efficacy of the subsequently delivered therapeutic agent 342. Similarly, delivering too little therapeutic agent 342 may fail to produce the desired therapeutic effect.
[0075] Although many surgeons and their assistants are skilled in ensuring that the proper amount of fluid is loaded into the syringe 50 before using the syringe 50 to deliver the fluid, it may be desirable to provide a device that can reliably and consistently ensure that the proper amount of fluid is loaded into the syringe 50 before using the syringe 50 to deliver the fluid, thereby allowing the patient to load only the proper amount of fluid into the syringe 50 without relying too much on the surgeon's personal skills, etc. An example of a dose clip assembly 400 is described below, which can be used with a conventional syringe such as the syringe 50 to consistently provide precision and accuracy in the amount of fluid loaded into the syringe; this can again be used as a reference to the above Figure 3-4G part of the procedure described to consistently provide precision and accuracy in the amount of fluid delivered to the subretinal space.
[0076] like Figure 5-7 As shown, the dose clamp assembly 400 of this example includes a lower member 500 and an upper member 600. The lower member 500 and the upper member 600 are pivotally coupled together by a pin 590. Figure 5-9 As shown, the lower member 500 includes a handle portion 510 and a barrel portion 520. The handle portion 510 is oriented vertically relative to the barrel portion 520. The handle portion 510 includes a pair of outwardly projecting finger flanges 512 and defines a slot 514. A boss 516 extends upwardly from one of the finger flanges 512. The barrel portion 520 includes an elongated cylindrical body 522 that defines a laterally existing groove 524. As described in more detail below, the groove 524 is configured to receive the barrel 710 of the syringe 700; and the slot 514 is configured to receive the finger flange 712 of the syringe 700.
[0077] The plunger stop portion 530 protrudes upward from the handle portion 510. Figure 8-9As best shown, the plunger stop portion 530 includes an upwardly presented plunger stop surface 532, a latch receiving recess 550 having a latch edge 552, and a pin receiving structure 570. As will be described in more detail below, the plunger stop surface 532 is configured to prevent advancement of the thumb flange 722 of the plunger 720 of the syringe 700. As will be described in more detail below, the latch receiving recess 550 is configured to receive the latch arm 640 of the upper member 600, and the latch edge 522 provides engagement with the latch arm 640, thereby maintaining the pivotal position of the upper member 600 relative to the lower member 500.
[0078] In the present example, the lower member 500 is made of plastic so that portions of the groove 524 and / or slot 514 can deform to frictionally retain the barrel 710 of the syringe 700. Alternatively, the lower member 500 may be made of any other suitable material or combination of materials.
[0079] like Figure 5-7 and Figure 10-11 As shown, the upper member 600 of this example includes a tab 610, a plunger retaining portion 620, a plunger stop portion 630, a latch arm 640, and a pin receiving structure 650. The tab 610 extends laterally relative to the longitudinal axis defined by the barrel portion 520 of the lower member 500. The plunger retaining portion 620 includes a ramp surface 622 and a lower surface 624. The plunger stop portion 630 includes a plunger stop surface 632 that is presented upward. As will be described in more detail below, the plunger stop surface 632 is configured to prevent the advancement of the thumb flange 722 of the plunger 720 of the syringe 700. As will also be described in more detail below, the lower surface 624 of the plunger retaining portion 620 is configured to prevent the plunger 720 from retracting proximally relative to the barrel 710 (e.g., otherwise it may be caused by the back pressure of the fluid contained in the barrel 710). As described above, the latch arm 640 is configured to engage the latch edge 522 of the latch receiving recess 550 of the lower member 500 , thereby maintaining the pivotal position of the upper member 600 relative to the lower member 500 .
[0080] In the present example, the upper member 600 is made of plastic, so at least a portion of the upper member 600 can be deformed to accommodate a portion of the thumb flange 722 between the lower surface 624 of the plunger grip 620 and the plunger stop surface 632 of the plunger stop portion 630. Alternatively, the upper member 600 can be made of any other suitable material or combination of materials.
[0081] As described above, the lower member 500 and the upper member 600 are pivotally coupled together by the pin 590, which is disposed in the pin receiving structure 570 of the lower member 500 and the pin receiving structure 650 of the upper member 600. This coupling enables the upper member 600 to be pivotally coupled relative to the lower member 500 in a first pivot position ( Fig. 12A ) and the second pivot position ( Fig. 12B ). When the upper member 600 is in the first pivot position relative to the lower member 500, the plunger stop portion 630 of the upper member 600 is positioned above the plunger stop portion 530 of the lower member 500, so that the plunger stop portion 630 will prevent the thumb flange 722 from being further advanced toward the plunger stop portion 530. When the upper member 600 is in the second pivot position relative to the lower member 500, the plunger stop portion 630 of the upper member 600 is positioned away from the plunger stop portion 530 of the lower member 500, so that the plunger stop portion 630 will no longer prevent the thumb flange 722 from being further advanced toward the plunger stop portion 530. In other words, when the upper member 500 is in the second pivot position relative to the lower member 600, the operator can freely advance the plunger 720 relative to the barrel 710 until the thumb flange 722 reaches the plunger stop surface 532.
[0082] like Fig. 12B As shown, a boss 516 on the handle portion 510 of the lower member 500 is used to engage the tongue 610 to prevent the upper member 600 from pivoting when the upper member 600 reaches the second pivot position relative to the lower member 500. In this example, the boss 516 is in the form of a pin that is integral with one finger flange 512 of the handle portion 510. Alternatively, any other suitable type of structure may be used to prevent the upper member 600 from pivoting relative to the lower member 500, as will be apparent to those skilled in the art in view of the teachings herein. The boss 516 is merely optional.
[0083] As mentioned above, Fig.13 As shown, when the upper member 600 is in the first pivot position relative to the lower member 500, the latch arm 640 engages with the latch edge 522. This engagement between the latch arm 640 and the latch edge 522 will substantially maintain the pivot position of the upper member 600 relative to the lower member 500, thereby substantially preventing accidental pivotal movement of the upper member 600 relative to the lower member 500. However, when the operator wishes to move the upper member 600 from the first pivot position ( Fig. 12A ) pivots to a second pivot position ( Fig. 12B), the latch arm 640 will be sufficiently deformed to allow the latch arm 640 to pass over the latch edge 552, thereby allowing the upper member 600 to pivot to the second pivot position. In some embodiments, at least a portion of the latch arm 640 is made of an elastic material so that when the upper member 600 repeatedly pivots between the first pivot position and the second pivot position, the latch arm 640 can repeatedly switch between the latched state and the unlocked state. In some other embodiments, at least a portion of the latch arm 640 (or a portion of the latch edge 552) is made of a frangible material so that after the upper member 600 has pivoted from the first pivot position to the second pivot position, the latch arm 640 and the latch edge 552 no longer achieve a latched relationship.
[0084] Figures 14A-14G An example of a dose clamp assembly 400 for use with a syringe 700 is shown. The syringe 700 of this example includes a barrel 710 and a plunger 720. The barrel 710 includes a finger flange 712. The plunger 720 includes a thumb flange 722 located at one end of a shaft 724 and a piston 726 located at the other end of the shaft 724. The piston 726 is sealingly disposed in the barrel 710 so that the longitudinal position of the piston 726 in the barrel 710 can be varied to selectively change the effective internal capacity of the barrel 710, which in turn affects the volume of the fluid contained in the barrel 710.
[0085] like Fig.14A As shown, the barrel 710 is initially coupled to a fluid source 800 via a conduit 802. In some cases, the fluid source 800 contains a pilot bubble 340 fluid. In other cases, the fluid source 800 contains a therapeutic agent 342 fluid. When the barrel 710 is initially coupled to the fluid source 800, the plunger 720 is in a distal position relative to the barrel 710. In addition, in this example, when the barrel 710 is initially coupled to the fluid source 800, the syringe 700 is completely decoupled from the dose clamp assembly 400.
[0086] With the barrel 710 fully coupled to the fluid source 800, the operator retracts the plunger 720 proximally relative to the barrel 710 to Fig. 14B During this proximal retraction of the plunger 720, the syringe 700 draws a volume of fluid from the fluid source 800 into the barrel 710. This volume will be greater than the volume of fluid that will ultimately be delivered to the subretinal space of the eye 301.
[0087] Once a volume of fluid is drawn from the fluid source 800 into the barrel 710, the syringe 700 is decoupled from the fluid source 800 and coupled to the dose clamp assembly 400. Fig. 14CAs shown, the barrel 710 is inserted into the groove 524 of the body 522; and the finger flange 712 is inserted into the narrow slot 514. In some aspects, the groove 524 is configured to provide a snap fit with the barrel 710, thereby substantially retaining the barrel 710 in the groove 524. In addition, or alternatively, the groove 524 may include one or more elastomeric features and / or other features configured to grasp or otherwise retain the barrel 710. In addition, or alternatively, the narrow slot 514 may include features configured to grasp or otherwise retain the finger flange 712. In this example, in Fig. 14C At the stage shown, the plunger 720 is still in a proximal position relative to the barrel 710; and the upper member 600 is in a second pivot position relative to the lower member 500. Alternatively, at this stage, the upper member 600 may already be in a first pivot position relative to the lower member 500.
[0088] Next, if Fig.14D As shown, the barrel 710 is coupled to the instrument 100 via the catheter assembly 140, and the barrel 710 and the instrument 100 are as described above. At this stage, the upper member 600 is not yet in the first pivot position relative to the lower member 500; at this stage, the upper member 600 can move to the first pivot position relative to the lower member 500.
[0089] arrive Fig.14D After the state shown, the operator can push the plunger 720 distally relative to the barrel 710 until it reaches Fig.14E This stage is also shown in stage 15A. At this stage, the thumb flange 722 is captured between the lower surface 624 of the plunger retaining portion 620 and the plunger stop surface 632 of the plunger stop portion 630. As the plunger 720 moves from Fig.14D The position shown transitions distally to Fig.14E In the position shown, the thumb flange 722 eventually engages the ramp surface 622 of the plunger catch 620. This engagement between the thumb flange 722 and the ramp surface 622 can provide a camming action that slightly deflects the plunger catch 620 away from the thumb flange 722 as the thumb flange 722 passes over the ramp surface 622. Once the thumb flange 722 passes over the ramp surface 622, the plunger catch 620 can snap back into place so that the lower surface 624 of the plunger catch 650 is positioned over a corresponding area of the thumb flange 722. In this example, the engagement between the latch arm 640 and the latch edge 522 is strong enough to prevent the upper member 600 from pivoting out of the first pivot position relative to the lower member 500 when the thumb flange 722 passes over the ramp surface 622.
[0090] In addition, from Fig.14D The status shown is Fig.14EDuring the transition period of the state shown, the plunger 720 drives a portion of the fluid from the barrel 710. This, in turn, can prime the catheter assembly 140 and the device 100 to clear air from the fluid path between the barrel 710 and the distal end of the needle 150. Fig.14D The status shown changes to Fig.14E During the state shown, the cannula 130 has not yet been inserted into the patient's eye 301.
[0091] like Fig.14E and 15A As shown in FIG. 1 , when the thumb flange 722 is caught between the lower surface 624 of the plunger retaining portion 620 and the plunger stop surface 632 of the plunger stop portion 630, the plunger 720 will neither be advanced distally relative to the barrel 710 nor retracted proximally relative to the barrel 710. Fig.14E and 15A In the illustrated state, the plunger stops 530, 630 cooperate to prevent the plunger 720 from translating longitudinally relative to the barrel 710. By preventing the plunger 720 from translating distally relative to the barrel 710, the plunger stops 530, 630 prevent the fluid from being accidentally discharged from the barrel 710; thereby preventing the fluid from being accidentally discharged from the needle 150. By preventing the plunger 720 from translating proximally relative to the barrel 710, the plunger stops 530, 630 prevent air or other fluid from being accidentally aspirated through the needle 150, which may otherwise occur when back pressure is accidentally generated in the fluid line between the distal end of the needle 150 and the barrel 710. Therefore, by preventing any longitudinal movement of the plunger 720 relative to the barrel 710, the plunger stops 530, 630 cooperate to maintain a predetermined volume of fluid in the barrel 710 and the entire fluid path between the barrel 710 and the distal end of the needle 150.
[0092] In reaching Fig.14E and 15A After the status shown, the operator can complete Figures 4A-4E In this example, the cartridge 710 contains fluid to form the leading bubble 340. To prepare the dose clamp assembly 400 to deliver the leading bubble 340, the operator can pivot the upper member 600 relative to the lower member 500 to the position shown in FIG. Fig.14F This can be achieved by engaging the tongue 610 with the thumb of the same hand that is gripping the body 522 of the barrel portion 520. Thus, the operator can easily move the dose clip assembly 400 from Fig.14E The state shown transitions to Fig.14F The status shown. Fig.14E The state shown changes to Fig.14FDuring the state shown, the latch arm 640 can be elastically deformed to disengage from the latch edge 522. Fig.14E The state shown changes to Fig.14F During the state shown, the plunger stop surface 632 is no longer positioned below the thumb flange 722 of the plunger 720. Therefore, when the dose clip assembly 400 is in Fig.14F In the state shown, the plunger 720 is moved relative to the barrel 710. Fig.14F The longitudinal position shown is freely advanced distally. In some cases, the operator is unable to move the upper member 600 from Fig.14E The first position shown is pivoted to Fig.14F until reaching the second position shown Figure 4E The program phases are shown.
[0093] Once the needle 150 has passed through the choroid 306 and is positioned to deliver fluid to the subretinal space (eg, Figure 4E ), and the upper member 600 has pivoted to the second position (as shown Fig.14F As shown in FIG. 1 , the operator can advance the plunger 720 distally relative to the barrel 710 until the thumb flange 722 engages the plunger stop surface 532 of the plunger stop portion 530 of the lower member 500. This state is Figure 14G and 15B As shown in FIG. 720, when the plunger 720 is moved from Fig.14F The longitudinal position shown goes to Figure 14G and 15B When in the longitudinal position shown, the plunger 720 drives a predetermined volume of fluid from the barrel 710. This provides fluid communication through the catheter assembly 140 and the associated components of the device 100, ultimately allowing the leading bubble 340 to be delivered (eg, Figure 4F ). The volume of fluid that forms the leading bubble 340 will be determined by the vertical distance between the plunger stop surface 632 of the plunger stop portion 630 and the plunger stop surface 532 of the plunger stop portion 530. Since the vertical distance between the surfaces 632, 532 is fixed and predetermined, the dose clamp assembly 400 will ensure that the syringe 700 consistently and predictably delivers a precise, predetermined volume of the leading bubble 340 of fluid. By way of example only, the predetermined volume of fluid can be in the range of about 50 microliters to about 300 microliters. In some embodiments, the predetermined volume of fluid is 100 microliters.
[0094] In some cases, the catheter assembly 140 is also in fluid communication with a combination of a second dose clamp assembly 400 and a second syringe 700, wherein the second syringe contains the therapeutic agent 342. As described above, the two syringes 700 can be connected to the catheter assembly 140 via a "Y" fitting or any other suitable component, which will be apparent to those skilled in the art in view of the teachings herein. In this case, the combination of the second dose clamp assembly 400 and the second syringe 700 can be accepted as described above with reference to Figures 14A-14G The same steps as described above. However, the plunger 720 of the first syringe 700 has been removed from Fig.14F The position shown in Figure 14G Before the lead bubble 340 is delivered, the plunger 720 of the second syringe 700 will not be moved from the Fig.14F The position shown in Figure 14G In other words, only after the leading bubble 340 has been delivered (as shown in FIG. Figure 4F As shown), the plunger 720 of the second syringe 700 will be Fig.14F The position shown is advanced to Figure 14G The position shown is to deliver the therapeutic agent 342 to the subretinal space (eg Figure 4G shown).
[0095] In the case of using two separate combinations including a dose clamp assembly 400 and a syringe 700 (one combination for the leading bubble 340 fluid and the other combination for the therapeutic agent 342 fluid), the corresponding dose clamp assembly 400 may have slightly different upper members 600 to provide different predetermined volumes of delivered fluid. For example, the upper member 600 used with the syringe 700 containing the fluid for the leading bubble 340 can be configured to deliver a first predetermined volume of fluid; while the upper member 600 used with the syringe 700 containing the therapeutic agent 342 can be configured to deliver a second predetermined volume of fluid. These different upper members 600 can vary based on the vertical position of their corresponding plunger stop surfaces 632. In other words, the different dose clamp assemblies 400 can vary based on the vertical distance between the plunger stop surfaces 532, 632. In addition to, or in the alternative to, varying this vertical distance by providing an upper member 600 of a different configuration, the lower member 500 may also be modified to provide different vertical distances between the plunger stop surfaces 532 , 632 .
[0096] As described above, the dose clip assembly 400 is configured to facilitate one-handed use. For example, the combination of the dose clip assembly 400 and the syringe 700 can be used in Figures 14C-14GAll stages shown are operated by the operator using only one hand to grasp the combination of the dose clip assembly 400 and the syringe 700. This can allow the operator's other hand to be free to manipulate the actuation knob 120 or other components of the device 100; or to perform other tasks. In addition, since the upper member 600 is Fig.14E The first position shown is pivoted to Fig.14F After the second position shown, the upper member 600 remains fixed to the lower member 500, so that when the dose clip assembly 400 is moved from Fig.14E The state shown changes to Fig.14F After the illustrated state, the operator does not need to use a second hand to handle the upper member 600. This can further simplify the disposal of the dose clip assembly 400 after the medical procedure is completed, so that the dose clip assembly 400 can be simply disposed of as a single unit rather than as separate components.
[0097] Although the foregoing examples provide applications of the combination of the dose clip assembly 400 and the syringe 700 in ophthalmic procedures, the combination of the dose clip assembly 400 and the syringe 700 may be used in various other types of medical procedures involving areas other than the eye 301 in the patient's body. Therefore, it is contemplated that the present invention need not be limited to use in ophthalmic procedures. Figures 4A-4G Various other suitable situations in which dose clip assembly 400 may be used will be apparent to those of ordinary skill in the art in view of the teachings herein.
[0098] 4. Combination Examples
[0099] The following examples relate to various non-exhaustive ways in which the teachings of this document may be combined or applied. The following examples are not intended to limit the coverage of any claims that may be raised at any time in this application or a subsequent application of this application. It is not intended to abandon the claims. The following examples are provided for illustrative purposes only. It is conceivable that the various teachings herein may be set and applied in a variety of other ways. It is also conceivable that some variations may omit certain features mentioned in the following examples. Therefore, unless the inventor or the inventor's heirs explicitly point out later, none of the aspects or features mentioned below should be considered essential. If any claim raised in this application or a subsequent application related to this application includes additional features in addition to the features mentioned below, these additional features should not be considered to be added for any reason related to patentability.
[0100] Example 1
[0101] A device includes: (a) a first member, the first member is configured to receive a portion of a syringe barrel, the first member includes a first stop surface, the first stop surface is configured to engage a portion of a plunger, thereby preventing the plunger from moving in a longitudinal direction relative to the syringe barrel; and (b) a second member, the second member is connected to the first member, the second member includes a second stop surface, the second stop surface is configured to engage the portion of the plunger, thereby preventing the plunger from moving in a longitudinal direction relative to the syringe barrel, and the second stop surface is spaced from the first stop surface; the second member is operable to move from a first position to a second position relative to the first member, the second member is configured to remain connected to the first member when in both the first position and the second position; the second stop surface is positioned to engage the portion of the plunger when the second member is in the first position, and the second stop surface is also configured to prevent the portion of the plunger from reaching the first stop surface when the second member is in the first position; the second stop surface is positioned so as not to prevent the portion of the plunger from reaching the first stop surface when the second member is in the second position.
[0102] Example 2
[0103] According to the device of Example 1, the first member includes: (i) an elongated body portion, and (ii) a handle portion extending transversely relative to the body portion.
[0104] Example 3
[0105] According to the device of Example 2, the body portion defines a recess configured to receive a syringe barrel.
[0106] Example 4
[0107] According to the device of Example 3, the body portion is configured to provide a snap fit with a syringe barrel.
[0108] Example 5
[0109] The device according to any one or more of Examples 2 to 4, the handle portion includes a slot configured to receive a finger flange of the syringe barrel.
[0110] Example 6
[0111] According to the device of any one or more of Examples 2 to 5, the handle portion includes a plunger stop portion extending upwardly from the handle portion, the body portion extends downwardly from the handle portion, and the plunger stop portion includes a first stop surface.
[0112] Example 7
[0113] According to the device of any one or more of Examples 1 to 6, the first stop surface is configured to prevent the plunger from moving distally in the longitudinal direction relative to the syringe barrel, and the second stop surface is configured to prevent the plunger from moving distally in the longitudinal direction relative to the syringe barrel.
[0114] Example 8
[0115] According to the device of any one or more of examples 1 to 7, the second member is pivotably coupled to the first member, the second member being operable to pivot from a first position to a second position relative to the first member.
[0116] Example 9
[0117] According to the device of Example 8, the device further includes a pin pivotably coupling the second member with the first member.
[0118] Example 10
[0119] According to the device of any one or more of Examples 1 to 9, the first stop surface and the second stop surface are configured to engage a thumb flange of the plunger to prevent movement of the plunger in a longitudinal direction relative to the syringe barrel.
[0120] Example 11
[0121] According to the device of any one or more of examples 1 to 10, when the second member is in the first position, the second stop surface is positioned proximally relative to the first stop surface.
[0122] Example 12
[0123] According to the device of any one or more of examples 1 to 11, when the second member is in the first position, the second stop surface is positioned proximally relative to the first stop surface.
[0124] Example 13
[0125] According to the device of Example 12, when the second member is in the first position, the second stop surface is positioned proximally relative to the first stop surface at a distance of about 1 mm to about 7 mm.
[0126] Example 14
[0127] According to the device of any one or more of examples 1 to 13, when the second member is in the first position, the second stop surface is laterally positioned relative to the first stop surface.
[0128] Example 15
[0129] According to the device of any one or more of examples 1 to 14, the second member further comprises a catch, the second member being configured to capture the portion of the plunger between the catch and the second stop surface when the second member is in the first position.
[0130] Example 16
[0131] According to the device of Example 15, the retaining portion includes a lower surface, which is configured to abut the upper surface of the finger flange of the plunger when the second member is in the first position, and the second stop surface is configured to abut the lower surface of the finger flange when the second member is in the first position.
[0132] Example 17
[0133] The device according to any one or more of Examples 1 to 16, further comprising a syringe comprising: (i) a barrel coupled to the first member, and (ii) a plunger slidably disposed in the barrel.
[0134] Example 18
[0135] According to the device of Example 17, the device further includes a delivery device, which includes: (i) a flexible sleeve, the sleeve is configured to fit between the choroid and the sclera of the patient's eye, and (ii) a needle slidably disposed in the sleeve, the needle defining an inner cavity connected to the barrel fluid of the syringe.
[0136] Example 19
[0137] According to the apparatus of Example 18, the device also includes an actuator operable to drive the needle in a longitudinal direction relative to the cannula, the needle being configured to penetrate the choroid to deliver fluid from the syringe barrel to the subretinal space in the patient's eye.
[0138] Example 20
[0139] A device comprises: (a) a first member, the first member is configured to receive a portion of a syringe barrel, the first member includes a first stop surface, the first stop surface is configured to engage a portion of a plunger, thereby preventing the plunger from moving distally in a longitudinal direction relative to the syringe barrel; and (b) a second member, the second member is connected to the first member, the second member includes: (i) a second stop surface, the second stop surface is configured to engage the portion of the plunger, thereby preventing the plunger from moving distally in a longitudinal direction relative to the syringe barrel, and (ii) a third stop surface, the third stop surface is configured to engage the portion of the plunger, thereby preventing the plunger from moving proximally in a longitudinal direction relative to the syringe barrel; the second member is operable to move from a first position to a second position relative to the first member; the second stop surface and the third stop surface are positioned to engage the portion of the plunger when the second member is in the first position; the second stop surface is positioned to allow the portion of the plunger to reach the first stop surface when the second member is in the second position.
[0140] Example 21
[0141] According to the device of Example 20, the second member is configured to remain coupled to the first member both in the first position and in the second position.
[0142] Example 22
[0143] A method comprises: (a) grasping an assembly comprising: (i) a dose clamp assembly, the dose clamp assembly comprising: (1) a first member, (2) a second member coupled to the first member, and (ii) a syringe, the syringe comprising: (1) a barrel disposed therein, and (2) a plunger slidably disposed within the barrel; (b) retracting the plunger proximally relative to the barrel, thereby drawing fluid from a fluid source into the barrel, the plunger being retracted to a first longitudinal position; (c) inserting the barrel of the syringe into the first member of the dose clamp assembly; (d) decoupling the fluid source from the barrel; and (e) disposing the barrel of the syringe in the dose clamp assembly. (f) moving the second member from the first position to the second position relative to the first member, wherein the second member in the second position no longer prevents the plunger from being further distally advanced relative to the barrel; and (g) advancing the plunger from the second longitudinal position to a third longitudinal position distally relative to the barrel when the second member is in the second position.
[0144] Example 23
[0145] According to the method of Example 22, during the act of inserting the barrel of the syringe into the first member of the dose clamp assembly, the second member is in the second position.
[0146] Example 24
[0147]
[00136] The method of any one or more of Examples 22-23 further includes coupling the cartridge to a fluid delivery device.
[0148] Example 25
[0149] The method of Example 24, wherein the act of coupling the barrel to the fluid delivery device is performed after the act of decoupling the fluid source from the barrel and before the act of advancing the plunger distally relative to the barrel to the second longitudinal position.
[0150] Example 26
[0151] According to the method of Example 25, the act of advancing the plunger distally relative to the barrel to the second longitudinal position primes the fluid path from the barrel to the fluid delivery portion of the fluid delivery device.
[0152] Example 27
[0153] According to the method of any one or more of Examples 22 to 26, after the action of advancing the plunger distally relative to the barrel to the second longitudinal position, the second member further prevents the plunger from retracting proximally relative to the barrel.
[0154] Example 28
[0155] According to the method of Example 27, the second member includes a catch that prevents the plunger from retracting proximally relative to the barrel.
[0156] Example 29
[0157] According to the method of Example 28, the act of advancing the plunger distally relative to the barrel to the second longitudinal position includes passing a portion of the plunger through a cam surface of the retaining portion.
[0158] Example 30
[0159]
[00136] According to the method of any one or more of Examples 22-29, the act of moving the second member from the first position to the second position relative to the first member includes pivoting the second member relative to the first member.
[0160] Example 31
[0161] According to the method of Example 30, after the action of moving the second member from the first position to the second position relative to the first member, the second member remains pivotably coupled to the first member.
[0162] Example 32
[0163] According to the method of any one or more of Examples 30 to 31, the first member includes a boss configured to limit the pivotal movement of the second member relative to the first member, such that when the second member reaches the second position, the boss prevents the pivotal movement of the second member.
[0164] Example 33
[0165] The method according to any one or more of Examples 22 to 32 further includes moving the second member from the second position to the first position prior to performing the action of advancing the plunger distally relative to the barrel to the second longitudinal position.
[0166] Example 34
[0167] According to the method of any one or more of Examples 22 to 33, when the plunger reaches the third longitudinal position, the first member blocks distal movement of the plunger, such that the first member prevents further distal advancement of the plunger relative to the barrel.
[0168] Example 35
[0169] According to the method of any one or more of Examples 22-33, the act of retracting the plunger proximally relative to the barrel to draw fluid from the fluid source into the barrel further includes retracting the plunger from the fourth longitudinal position to the first longitudinal position.
[0170] Example 36
[0171] According to the method of Example 36, the fourth longitudinal position is located distal to the third longitudinal position.
[0172] Example 37
[0173] According to the method of any one or more of Examples 22 to 36, the act of decoupling the fluid source from the barrel is performed before the act of inserting the barrel of the syringe into the first member of the dose clamp assembly.
[0174] Example 38
[0175] According to the method of any of Examples 22 to 37, the actions of moving the second member from the first position to the second position relative to the first member and advancing the plunger distally from the second longitudinal position to the third longitudinal position relative to the barrel are performed using only one hand.
[0176] Example 39
[0177] According to the method of Example 38, during the action of moving the second member from a first position to a second position relative to the first member and the action of advancing the plunger distally from a second longitudinal position to a third longitudinal position relative to the barrel, the fingers of one hand are used to grasp the first member and the thumb of one hand is used to move the second member from a first position to a second position relative to the first member.
[0178] Example 40
[0179] According to the method of any one or more of Examples 22 to 39, the fluid source includes a fluid selected from the group consisting of a pilot bubble fluid and a therapeutic agent.
[0180] V. Miscellaneous
[0181] Any type of apparatus described herein may include various other features in addition to or in place of the above features. By way of example only, any device herein may also include one or more of the various features disclosed in any of the references incorporated herein by reference.
[0182] Any one or more of the teachings, statements, embodiments, examples, etc. described herein may be combined with any one or more of the other teachings, statements, embodiments, examples, etc. described herein. Therefore, the above teachings, statements, embodiments, examples, etc. should not be viewed in isolation from each other. In view of the teachings herein, it will be apparent to those skilled in the art that various suitable ways of combining the teachings herein are possible. Such modifications and variations are intended to be included within the scope of the claims.
[0183] It should be understood that any patent, publication, or other public material (in whole or in part) incorporated herein by reference is incorporated herein only to the extent that the incorporated material does not conflict with existing definitions, statements, or other public materials set forth in the present disclosure. Therefore, where necessary, the disclosure explicitly set forth herein can supersede any conflicting material incorporated herein by reference. Any material or portion thereof incorporated herein that conflicts with existing definitions, statements, or other public materials set forth herein will be incorporated only to the extent that the incorporated material does not conflict with existing public materials.
[0184] The above types can be designed to be discarded after a single use, or can be designed to be used multiple times. In any one case or both cases, the type can be refurbished for reuse after at least one use. Renovation can include any combination of the following steps: disassembling the equipment, subsequently cleaning or replacing specific parts, and subsequently reassembling. In particular, some types of the equipment can be disassembled, and any number of specific parts or components of the equipment can be selectively replaced or removed in any combination. When cleaning and / or replacing specific parts, some types of equipment can be reassembled at a renovation facility for subsequent use, or reassembled by the operator before the procedure. Those skilled in the art will appreciate that the renovation of equipment can utilize various disassembly, cleaning / replacement and reassembly techniques. The use of these technologies and the resulting renovation rear equipment all fall within the scope of the present application.
[0185] By way of example only, the types described herein may be sterilized before and / or after the procedure. In one sterilization technique, the device is placed in a closed, sealed container, such as a plastic bag or a TYVEK bag. The container and device may then be placed in a field of radiation that can penetrate the container, such as gamma radiation, x-rays, or a high-energy electron field. The radiation can kill bacteria on the device and bacteria in the container. The sterilized device may then be stored in a sterile container for subsequent use. The device may also be sterilized using any other technique known in the art, including but not limited to beta or gamma radiation, ethylene oxide, or steam.
[0186] Various embodiments of the present invention have been shown and described, and further adjustments to the methods and systems described herein may be accomplished by appropriate modifications by one of ordinary skill in the art without departing from the scope of the present invention. Several such potential modifications have been mentioned, and other modifications will be apparent to one of ordinary skill in the art. For example, the examples, embodiments, geometries, materials, dimensions, ratios, steps, etc. discussed above are illustrative and not required. Therefore, the scope of the present invention should be considered in light of the following claims, and should be understood not to be limited to the details of the structures and operations shown and described in the specification and drawings.
Claims
1. A device, the device include: (a) a first member configured to receive a portion of a syringe barrel, the first member comprising a first stop surface configured to engage a portion of a plunger to prevent longitudinal movement of the plunger relative to the syringe barrel; and (b) a second member coupled to the first member, the second member comprising a second stop surface configured to engage the portion of the plunger to prevent longitudinal movement of the plunger relative to the syringe barrel, the second stop surface being spaced apart from the first stop surface; the second member being operable to move relative to the first member from a first position to a second position, the second member being configured to remain coupled to the first member in both the first position and the second position; the second stop surface being positioned to engage the portion of the plunger when the second member is in the first position, the second stop surface being further configured to prevent the portion of the plunger from reaching the first stop surface when the second member is in the first position; The second stop surface is positioned to not prevent the portion of the plunger from reaching the first stop surface when the second member is in the second position.
2. The device according to claim 1, wherein the first member include: (i) an elongated main body portion, and (ii) a handle portion extending transversely relative to the main body portion.
3. The device of claim 2, wherein the body portion defines a recess configured to receive the syringe barrel.
4. The device of claim 3, wherein the body portion is configured to provide a snap fit with the syringe barrel.
5. The device of any one or more of claims 2 to 4, the handle portion comprising a slot configured to receive a finger flange of the syringe barrel.
6. The device of any one or more of claims 2 to 5, the handle portion comprising a plunger stop portion extending upwardly from the handle portion, the body portion extending downwardly from the handle portion, the plunger stop portion comprising the first stop surface.
7. According to the device described in any one or more of claims 1 to 6, the first stop surface is configured to prevent the distal longitudinal movement of the plunger relative to the syringe barrel, and the second stop surface is configured to prevent the distal longitudinal movement of the plunger relative to the syringe barrel.
8. Apparatus according to any one or more of claims 1 to 7, the second member being pivotably coupled to the first member, the second member being operable to pivot relative to the first member from the first position to the second position.
9. The device of claim 8, further comprising a pin pivotably coupling the second member with the first member.
10. The device of any one or more of claims 1 to 9, the first stop surface and the second stop surface being configured to engage a thumb flange of the plunger to prevent longitudinal movement of the plunger relative to the syringe barrel.
11. The device of any one or more of claims 1 to 10, the second stop surface being positioned proximally relative to the first stop surface when the second member is in the first position.
12. The device of any one or more of claims 1 to 11, wherein the second stop surface is positioned proximally relative to the first stop surface when the second member is in the first position.
13. The device of claim 12, wherein the second stop surface is positioned proximally relative to the first stop surface at a distance of about 1 mm to about 7 mm when the second member is in the first position.
14. Apparatus according to any one or more of claims 1 to 13, wherein the second stop surface is positioned laterally relative to the first stop surface when the second member is in the first position.
15. The device of any one or more of claims 1 to 14, the second member further comprising a catch, the second member being configured to capture the portion of the plunger between the catch and the second stop surface when the second member is in the first position.
16. The device of claim 15, wherein the retaining portion includes a lower surface configured to abut an upper surface of a finger flange of the plunger when the second member is in the first position, and the second stop surface is configured to abut a lower surface of the finger flange when the second member is in the first position.
17. The device according to any one or more of claims 1 to 16, further comprising a syringe, the syringe include: (i) a cartridge coupled to the first member, and (ii) a plunger slidably disposed in the barrel.
18. The device of claim 17, further comprising a delivery device, the delivery device include: (i) a flexible cannula configured to fit between the choroid and sclera of the patient's eye, and (ii) a needle slidably disposed in the cannula, the needle defining a lumen in fluid communication with the barrel of the syringe.
19. The apparatus of claim 18, the device further comprising an actuator operable to drive the needle longitudinally relative to the cannula, the needle being configured to penetrate the choroid to deliver fluid from the syringe barrel to the subretinal space in the patient's eye.
20. A device, the device include: (a) a first member configured to receive a portion of a syringe barrel, the first member comprising a first stop surface configured to engage a portion of a plunger to prevent distal longitudinal movement of the plunger relative to the syringe barrel; and (b) a second member, the second member being coupled to the first member, the second member comprising: (i) a second stop surface configured to engage the portion of the plunger to prevent distal longitudinal movement of the plunger relative to the syringe barrel, and (ii) a third stop surface configured to engage the portion of the plunger to prevent proximal longitudinal movement of the plunger relative to the syringe barrel; the second member being operable to move from a first position to a second position relative to the first member; the second stop surface and the third stop surface being positioned to engage the portion of the plunger when the second member is in the first position; The second stop surface is positioned to allow the portion of the plunger to reach the first stop surface when the second member is in the second position.
21. The device of claim 20, the second member being configured to remain coupled to the first member in both the first position and the second position.
22. A method, include: (a) grasping a component, the component comprising: (i) a dose clamp assembly, the dose clamp assembly comprising: (1) a first component, (2) a second member connected to the first member, and (ii) a syringe, the syringe comprising: (1) the cylinder provided, and (2) a plunger slidably disposed within the barrel; (b) retracting the plunger proximally relative to the barrel to draw fluid from a fluid source into the barrel, the plunger being retracted to a first longitudinal position; (c) inserting the barrel of the syringe into the first member of the dose clamp assembly; (d) decoupling the fluid source from the cartridge; (e) with the barrel of the syringe disposed in the first member of the dose gripper assembly and the second member in a first position relative to the first member, advancing the plunger distally relative to the barrel to a second longitudinal position, the plunger engaging the second member at the second longitudinal position, the second member in the first position preventing further distal advancement of the plunger relative to the barrel; (f) moving the second member relative to the first member from the first position to a second position in which the second member no longer prevents further distal advancement of the plunger relative to the barrel; and (g) with the second member in the second position, advancing the plunger distally relative to the barrel from the second longitudinal position to a third longitudinal position.
23. The method of claim 22, wherein during the act of inserting the barrel of the syringe into the first member of the dose gripper assembly, the second member is in the second position.
24. The method of any one or more of claims 22-23, further comprising coupling the cartridge to a fluid delivery device.
25. The method according to claim 24, in, The act of coupling the barrel with a fluid delivery device is performed after the act of decoupling the fluid source from the barrel and before the act of advancing the plunger distally relative to the barrel to the second longitudinal position.
26. The method of claim 25, the act of advancing the plunger distally relative to the barrel to the second longitudinal position priming a fluid path from the barrel to a fluid delivery portion of the fluid delivery device.
27. The method of any one of claims 22 to 26, wherein the second member further prevents the plunger from being retracted proximally relative to the barrel following the act of advancing the plunger distally relative to the barrel to the second longitudinal position.
28. The method of claim 27, the second member comprising a catch that prevents the plunger from proximally retracting relative to the barrel.
29. The method of claim 28, the act of advancing the plunger distally relative to the barrel to the second longitudinal position comprising passing a portion of the plunger through a cam surface of the catch.
30. The method of any one of claims 22 to 29, the act of moving the second member from the first position to the second position relative to the first member comprising pivoting the second member relative to the first member.
31. The method of claim 30, wherein after the act of moving the second member relative to the first member from the first position to the second position, the second member remains pivotally coupled to the first member.
32. According to any one or more of claims 30 to 31, the first member includes a boss, which is constructed to limit the pivotal movement of the second member relative to the first member, so that when the second member reaches the second position, the boss prevents the pivotal movement of the second member.
33. The method of any one or more of claims 22 to 32, further comprising moving the second member from the second position to the first position prior to advancing the plunger distally relative to the barrel to the second longitudinal position.
34. The method of any one or more of claims 22 to 33, wherein the first member resists distal movement of the plunger when the plunger reaches the third longitudinal position, such that the first member prevents further distal advancement of the plunger relative to the barrel.
35. The method of any one or more of claims 22 to 33, wherein the act of retracting the plunger proximally relative to the barrel to draw fluid from the fluid source into the barrel further comprises retracting the plunger from a fourth longitudinal position to the first longitudinal position.
36. The method of claim 36, wherein the fourth longitudinal position is distal to the third longitudinal position.
37. The method of any one or more of claims 22 to 36, the act of decoupling the fluid source from the barrel being performed prior to the act of inserting the barrel of the syringe into the first member of the dose gripper assembly.
38. The method according to any one or more of claims 22 to 37, wherein the actions of moving the second member from the first position to the second position relative to the first member and advancing the plunger distally from the second longitudinal position to the third longitudinal position relative to the barrel are performed using only a single hand.
39. According to the method of claim 38, during the action of moving the second member from the first position to the second position relative to the first member and the action of advancing the plunger distally from the second longitudinal position to the third longitudinal position relative to the barrel, the fingers of the single hand are used to grasp the first member, and the thumb of the single hand is used to move the second member from the first position to the second position relative to the first member.
40. The method of any one or more of claims 22 to 39, wherein the fluid source comprises a fluid selected from the group consisting of a pilot bubble fluid and a therapeutic agent.
